CoChat

Interaction of tumor-associated macrophages and cancer chemotherapy

Open access
Larionova, Irina, Cherdyntseva, Nadezhda, Liu, Tengfei, Patysheva, Marina, Rakina, Militsa, Kzhyshkowska, Julia · 2019 · OncoImmunology

The DOI matches its Crossref record; 123 of the 124 references it cites were found in a registry or an index.

Abstract

It has been recently recognized that the tumor microenvironment (TME) is an essential factor that defines the efficiency of chemotherapy. The local TME, consisting of immune cells with diverse phenotypes and functions, can strongly modulate the response to chemotherapy. Tumor-associated macrophages (TAMs) that display pronounced heterogeneity and phenotypic plasticity are the major innate immune component in the microenvironment of solid tumors. In our review, we elucidate the complex role of TAMs in the progression of different types of solid tumors, summarize the current knowledge about the effects of different anticancer chemotherapeutic agents on monocytes/macrophages, and describe the mechanisms of chemotherapy resistance mediated by TAMs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2019.1596004

Cites

123 of 123 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. The mechanisms of action of the main chemotherapeutic agents. There are several mechanisms by which chemotherapeutic agents act in the cancer cell (a) intercalate into DNA and disrupt topoisomerase-II-mediated DNA repair (doxorubicin); (b) promote microtubule polymerization and stabilization (paclitaxel and docetaxel); (c) form DNA crosslinks (cisplatin, carboplatin); (d) inhibit thymidylate synthase (TS) (5-fluorouracil); (e) act as pyrimidine nucleoside antimetabolite (gemcitabine); (f) bind to the minor groove of the DNA (trabectedin). Commonly, all of them cause inhibition the DNA replication and transcription and cancer cell death. The detailed explanation is given in the paragraph “Cancer chemotherapy, chemoresistance and immunomodulation”.
Figure 1. The mechanisms of action of the main chemotherapeutic agents. There are several mechanisms by which chemotherapeutic agents act in the cancer cell (a) intercalate into DNA and disrupt topoisomerase-II-mediated DNA repair (doxorubicin); (b) promote microtubule polymerization and stabilization (paclitaxel and docetaxel); (c) form DNA crosslinks (cisplatin, carboplatin); (d) inhibit thymidylate synthase (TS) (5-fluorouracil); (e) act as pyrimidine nucleoside antimetabolite (gemcitabine); (f) bind to the minor groove of the DNA (trabectedin). Commonly, all of them cause inhibition the DNA replication and transcription and cancer cell death. The detailed explanation is given in the paragraph “Cancer chemotherapy, chemoresistance and immunomodulation”.CC BY-NC-ND · PubMed Central
Figure 2. The mechanisms of macrophage-mediated resistance to chemotherapy. The pathways responsible for the tumor-promoting function of TAMs after chemotherapy and chemoresistance include the increased recruitment of immunosuppressive TAMs, the pro-tumor polarization, the reduced T-cell cytotoxic response, the activation of anti-apoptotic programs in malignant cells. a. TAMs which contribute to tumor resistance to doxorubicin have high expression of CD68, CD206, CD163, PD-L1, but low expression of CD80 and CD86. Moreover, TAMs release immunosuppressive cytokines (IL10 and TGFβ), factors which promote invasion (MMP9, MMP13), pro-angiogenic factor VEGF which cause revascularization. Increased expression of PDL1 in TAMs limits tumor response to chemotherapy by suppression the antitumor functions of cytotoxic T cells resulting in tumor cell survival and proliferation, and chemoresistance. b. TAM-mediated resistance to carboplatin is associated with STAT3 signaling and macrophage-produced IL6 promoting tumor cell growth. TAM exosomes are involved in cisplatin resistance via the activation of the PI3K/AKT signaling pathway in tumor cells. c. Chemoresistance to gemcitabine is mediated by decreasing the activation of caspase-3 and reducing the apoptosis in tumor cells. d. Cathepsin proteases (cathepsin B and S) secreted by TAMs mediate chemoprotection through NF-κβ activation, or indirectly through IL-6 expression and STAT3 activation. There are unknown mechanisms of chemotherapy influence on macrophages.
Figure 2. The mechanisms of macrophage-mediated resistance to chemotherapy. The pathways responsible for the tumor-promoting function of TAMs after chemotherapy and chemoresistance include the increased recruitment of immunosuppressive TAMs, the pro-tumor polarization, the reduced T-cell cytotoxic response, the activation of anti-apoptotic programs in malignant cells. a. TAMs which contribute to tumor resistance to doxorubicin have high expression of CD68, CD206, CD163, PD-L1, but low expression of CD80 and CD86. Moreover, TAMs release immunosuppressive cytokines (IL10 and TGFβ), factors which promote invasion (MMP9, MMP13), pro-angiogenic factor VEGF which cause revascularization. Increased expression of PDL1 in TAMs limits tumor response to chemotherapy by suppression the antitumor functions of cytotoxic T cells resulting in tumor cell survival and proliferation, and chemoresistance. b. TAM-mediated resistance to carboplatin is associated with STAT3 signaling and macrophage-produced IL6 promoting tumor cell growth. TAM exosomes are involved in cisplatin resistance via the activation of the PI3K/AKT signaling pathway in tumor cells. c. Chemoresistance to gemcitabine is mediated by decreasing the activation of caspase-3 and reducing the apoptosis in tumor cells. d. Cathepsin proteases (cathepsin B and S) secreted by TAMs mediate chemoprotection through NF-κβ activation, or indirectly through IL-6 expression and STAT3 activation. There are unknown mechanisms of chemotherapy influence on macrophages.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 123 references

Research works printed but not linked: 7

  1. Chen JJW, 2003, Clin Cancer Res, 9, 729
  2. Makitie T, 2001, Invest Ophthalmol Vis Sci, 42, 1414
  3. Yang J, 2015, Int J Clin Exp Pathol, 8, 6656
  4. Yafei Z, 2016, Biomed Res, 27, 305
  5. 10.1111/apm.2016.124.issue-6 · DOI
  6. 10.1111/j.1365-2567.2010.03357 · doi:10.1111/j.1365-2567.2010.03357
  7. 10.1046/j.1440-1711.1998.00769 · doi:10.1046/j.1440-1711.1998.00769

Cited by

See all 334

Metadata

Authors
Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M., & Kzhyshkowska, J.
Affiliations
  • Russian Academy of Sciences (RU)
  • Laboratory of Translational Cellular and Molecular Biomedicine, National Research Tomsk State University, Tomsk, Russia
  • Heidelberg University (DE)
  • National Research Tomsk State University (RU)
Corresponding author
Kzhyshkowska, Julia
Venue
OncoImmunology
Published
2019-04-13
Volume
8
Issue
7
Pages
e1596004
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W2939258716
Cited by
322
References
124
Citations by year
2026: 18 · 2025: 37 · 2024: 53 · 2023: 46 · 2022: 65 · 2021: 59 · 2020: 37 · 2019: 7
FWCI
3.62
Type
journal article
Language
en
Open access
Locations
  • OncoImmunology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Russian Science Foundation
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
Keywords
tumor-associated macrophages, tumor microenvironment, chemotherapy response, chemoresistance, solid tumors, monocytes, macrophage heterogeneity, phenotypic plasticity, innate immunity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interaction of tumor-associated macrophages and cancer chemotherapy. https://app.cochat.ai/papers/10.1080/2162402x.2019.1596004
The paper
Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M., & Kzhyshkowska, J. (2019). Interaction of tumor-associated macrophages and cancer chemotherapy. OncoImmunology. https://doi.org/10.1080/2162402x.2019.1596004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.